Journal
HUMAN PATHOLOGY
Volume 64, Issue -, Pages 69-75Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2017.03.007
Keywords
SALL4; HDAC1; HDAC2; PTEN; Hepatocellular carcinoma
Categories
Funding
- Grants-in-Aid for Scientific Research [17K08722] Funding Source: KAKEN
Ask authors/readers for more resources
Spalt-like transcriptional factor 4 (SALL4), a stem marker, is reactivated in several cancers. A previous study has demonstrated that SALL4 interacts with the nucleosome remodeling deacetylase complex, which contains histone deacetylase 1 (HDACI) and histone deacetylase 2 (HDAC2). In this study, we investigated the expression status of SALL4, HDACI, and HDAC2 and their relationship with phosphatase and tens in homolog deleted on chromosome 10 (PTEN) by immunohistochemical analysis of the posthepatectomy specimens of 135 patients with hepatocellular carcinoma who were treated at our hospital. Ninetytwo frozen samples were subjected to quantitative reverse -transcription polymerase chain reaction analysis to detect the messenger RNA levels of PTEN. Seventy-six (56%) of 135 patients were positive for SALL4, and this group had a higher prevalence of hepatitis B antigen, a higher value of a-fetoprotein (AFP) and protein induced by vitamin K absence (PIVKAII) and poor histologic differentiation. The 5-year survival rate was significantly lower in the SALL4-positive group. High HDACI expression (51 %) was correlated with a poor histologic differentiation and a poor prognosis. High HDAC2 expression (46%) was associated with a higher prevalence of hepatitis B antigen positivity, a poor histologic differentiation and higher prevalence of vascular invasion, and a lower 5-year survival rate. Coexpression of SALL4 with HDACI and/or HDAC2 was correlated with underexpression of PTEN. Moreover, multivariable analysis revealed that coexpression of SALL4 with HDAC I and/or HDAC2 was predictive of an unfavorable prognosis. Our data thus suggested that the combination of SALL4, HDACI, and HDAC2 may provide a potential target for molecular therapy. (C) 2017 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available